News

The U.S. Food and Drug Administration (FDA) is giving priority review to a request that the oral therapy Evrysdi (risdiplam) be approved to treat pre-symptomatic infants with spinal muscular atrophy (SMA) who are less than 2 months old. Priority review is given to therapies with the potential to substantially…

Within the U.S., there is marked state-to-state variation in guidelines for whether Medicaid will cover Spinraza (nusinersen) or Zolgensma (onasemnogene abeparvovec) treatments, according to a new study. This finding raises concerns about equitable access to these lifesaving therapies for spinal muscular atrophy (SMA), according to researchers. The…

Targeted next generation sequencing (NGS) — a powerful genetic method that can identify mutations in several genes simultaneously — is superior to two commonly used genetic tests for the screening of spinal muscular atrophy (SMA), a study shows. These findings highlight targeted NGS as a reliable and promising approach…

Caregivers of children with spinal muscular atrophy (SMA) said they need information about institutions that may benefit their child in the future, a questionnaire-based study suggested. Although caregivers’ burden was not directly related to income or disease type, increased burden was disease-related, the scientists said. The study, “…

An adolescent male with spinal muscular atrophy (SMA) receiving tube feeding and antibiotics developed a problem with blood clotting due to a deficiency in vitamin K, a case study reported. “This case highlights that nutritional vitamin K deficiency should be considered in complex chronic pediatric patients whose nutritional needs…

Individuals that are sedentary, like my patient Michael, are more prone to having kidney stones secondary to too little activity as well as possible reduced fluid intake due to other restrictions, such as reduced upper extremity strength and ability to self-nourish. In the past 20 years, Michael has undergone surgery…

Despite its well-reported benefits in motor function, Spinraza (nusinersen) may not be as effective at preventing or easing nonmotor complications, such as facial deformities, feeding problems, and scoliosis, in children with spinal muscular atrophy (SMA) type 1. Given that all these complications may affect the child’s lung function…

Motor neurons derived from people with spinal muscular atrophy (SMA) showed changes in protein production at each stage of their development, from stem cells to fully mature nerve cells, a study discovered. Findings in this reported first-such study can be used to identify protein alterations that occur before the…

The muscle atrophy and weakness characteristic of spinal muscular atrophy (SMA) is aggravated by the loss of fast-contracting white muscle fibers in patients with later-onset disease, an MRI study showed, reportedly for the first time. Production of the energy molecule ATP was also found to be impaired in white…

Before the emergence of Spinraza (nusinersen) — the first disease-modifying therapy (DMT) approved for spinal muscular atrophy (SMA) — patients of all ages and types of the disease showed greater all-cause mortality than their peers who did not have SMA and the general population, according to a large study…